The Effects of Anlotinib Combined with Chemotherapy following Progression on Cyclin‐Dependent Kinase 4/6 Inhibitor in Hormone Receptor‐Positive Metastatic Breast Cancer
Open Access
- 1 January 2024
- journal article
- research article
- Published by Wiley in The Breast Journal
- Vol. 2024 (1) , 5396107
Abstract
Purpose. Endocrine therapy combined with cyclin‐dependent kinase (CDK) 4/6 inhibitors (CDK4/6i) is the preferred treatment for hormone receptor‐positive (HR+)/human epidermal growth factor receptor 2‐negative (HER2–) metastatic breast cancer (MBC). However, there are currently no recommendations for therapeutic strategies after progression on CDK4/6i‐based treatment. This study aimed to examine the efficacy and safety of anlotinib plus chemotherapy in HR+/HER2– MBC after progression on CDK4/6 inhibitors. Methods. We collected data from 32 patients with HR+/HER2– MBC treated with anlotinib plus chemotherapy after progressing on CDK4/6i at Jiangsu Cancer Hospital from March 2020 to October 2023. The median follow‐up was 9.1 months (range, 2.0–19.7 months) as of the data cutoff date in October 2023. The primary endpoint was median progression‐free survival (PFS); secondary endpoints included objective response rate (ORR), disease control rate (DCR), and adverse events. Results. The median PFS (mPFS) of all patients was 7.6 months (95% confidence interval (CI), 5.75–9.45). There was no significant difference in mPFS between patients who responded to prior CDK4/6i treatment and those who did not (8.3 months vs. 6.8 months, p = 0.580). Besides, the ORR was 34.4% and DCR was 93.8%. The most frequently observed adverse events were anemia (50.0%), neutropenia (40.6%), thrombocytopenia (34.4%), and epistaxis (34.4%). Dose interruption or reductions due to adverse events occurred in 2 (6.3%) and 5 (15.6%) patients, respectively. Conclusions. The study preliminarily demonstrates that anlotinib combined with chemotherapy may be an optional recommendation for patients with HR+/HER2– metastatic breast cancer who have progressed after CDK4/6i.Keywords
Funding Information
- Beijing Xisike Clinical Oncology Research Foundation (Y-Young2022—0072)
This publication has 16 references indexed in Scilit:
- Clinical outcomes of tucidinostat-based therapy after prior CDK4/6 inhibitor progression in hormone receptor-positive heavily pretreated metastatic breast cancerThe Breast, 2022
- Effectiveness of Alpelisib + Fulvestrant Compared with Real-World Standard Treatment Among Patients with HR+, HER2–, PIK3CA-Mutated Breast CancerThe Oncologist, 2021
- Alpelisib plus fulvestrant in PIK3CA-mutated, hormone receptor-positive advanced breast cancer after a CDK4/6 inhibitor (BYLieve): one cohort of a phase 2, multicentre, open-label, non-comparative studyThe Lancet Oncology, 2021
- Bleeding with vascular endothelial growth factor tyrosine kinase inhibitor: A network meta-analysisCritical Reviews in Oncology/Hematology, 2021
- Everolimus Plus Exemestane Treatment in Patients with Metastatic Hormone Receptor-Positive Breast Cancer Previously Treated with CDK4/6 Inhibitor TherapyThe Oncologist, 2020
- CDK4/6 Inhibitors Expand the Therapeutic Options in Breast Cancer: Palbociclib, Ribociclib and AbemaciclibBioDrugs, 2019
- MONARCH 3 final PFS: a randomized study of abemaciclib as initial therapy for advanced breast cancernpj Breast Cancer, 2019
- Anlotinib: First Global ApprovalDrugs, 2018
- Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancerAnnals of Oncology, 2018
- Palbociclib and Letrozole in Advanced Breast CancerNew England Journal of Medicine, 2016